Elevated GH levels subsequently trigger the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic effects, including protein synthesis, lipolysis (fat breakdown), and tissue repair
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
Consider tirzepatide (Zepbound/Mounjaro) if: You want a proven, FDA-approved medication available today You prefer a drug with years of real-world safety data You have insurance coverage for weight management medications You have type 2 diabetes (Mounjaro is indicated for T2D) You are sensitive to GI side effects (lower nausea rate: 31% vs 43%) You want the option of pre-filled pens for easier injection Consider waiting for retatrutide if: You have plateaued on tirzepatide or semaglutide and want the next-generation option You have MASLD or fatty liver disease (glucagon component reduces liver fat by 82%) Maximum possible weight loss is your primary goal You are eligible for and enrolled in a clinical trial You are comfortable waiting until 2027-2028 for availability On switching from tirzepatide to retatrutide: Once retatrutide is approved, switching will likely be straightforward since both are Lilly products
Because the drugs treat and help manage obesity, insulin resistance, inflammation, and your metabolism, they can also affect skin diseases connected to those conditions
Your lifestyle: Are you willing to inject yourself once a week, or would you prefer a daily pill
The cardiovascular outcome trials that will run for several years have not yet been initiated for Retatrutide
